

PREVALENCE OF METALLO- β -LACTAMASE PRODUCING PSEUDOMONAS AERUGINOSA IN TERTIARY CARE CENTER IN EASTERN NEPAL

Gurung R¹, Shrestha S², Baral R¹, Poudyal N¹, Khanal B¹

¹Department of Microbiology, BPKIHS, Dharan, ²Department of Microbiology, Nepal Medical College, Kathmandu

ABSTRACT

Carbapenem resistance in *Pseudomonas aeruginosa* is an emerging threat and matter of concern, therefore detection of *metallo- β -Lactamase* (MBL) - producing *P. aeruginosa* is crucial in preventing its spread to other Gram negative bacteria. This study is aimed to determine the prevalence of MBL production and antimicrobial resistance in *P. aeruginosa* isolated from in-patients and out-patients of a tertiary care center in Eastern Nepal. Identification and antimicrobial susceptibility pattern of isolated *P. aeruginosa* from different clinical samples received in Microbiology laboratory was performed following CLSI guidelines and MBL production was determined by IPM-EDTA - disk synergy test. A total of 137 *P. aeruginosa* strains were isolated from different clinical samples, out of which 79.6% isolates were resistant to Carbapenem, among them 35.78% isolates were MBL producer. Overall prevalence of MBL production among *P. aeruginosa* was found to be 31.4%. This study reveal high level of resistance being exhibited by a notorious organism like *P. aeruginosa* to commonly used antimicrobials for treatment of infection, and an alarming threat of MBL production necessitating a routine screening for MBL production. Also a more effective, less toxic and cheap antimicrobial for the future is imperative.

KEYWORDS

Antimicrobial resistance, metallo beta lactamase, pseudomonas aeruginosa

CORRESPONDING AUTHOR

Dr. Rajendra Gurung (MD),
Department of Microbiology,
BPKIHS, Dharan, Nepal
Email: drrajendragrg@gmail.com

INTRODUCTION

Infection caused by *Pseudomonas aeruginosa* (*P. aeruginosa*) is common, with the burden of infection mostly among hospitalized patients. It is reported to be the second most common organism isolated in nosocomial pneumonia, the third most common organism isolated in both urinary tract infections (UTIs) and surgical site infections (SSIs), and the fifth most common organism isolated from all sites of nosocomial infection.¹ The problem of antibiotic resistance in *P. aeruginosa* is on the increase.² Frequently encountered multidrug-resistant (MDR) bacterial isolates like Ceftazidime-resistant *P. aeruginosa* is common and prevalent in a hospital environment.³

MDR *P. aeruginosa* is inherently resistant to many drug classes and is able to acquire resistance to all effective antimicrobial drugs⁴, it elaborates inactivating enzymes that make beta-lactams and carbapenems ineffective, such as Extended Spectrum Beta Lactamases (ESBLs) and Metallo-β-lactamases (MBLs).⁵ Consequently, treatment options are narrowed down to a few antibiotics. Carbapenems are the antibiotics of choice for severe pseudomonas infections.⁶ However, there is paucity data from Nepal, which have systematically studied the underlying mechanisms for MBL resistance among *P. aeruginosa* isolates. Therefore, this prospective study was carried out to determine the prevalence of MBL production and antimicrobial resistance in *P. aeruginosa* isolated from different clinical samples received from in-patients and the out-patients of a tertiary care center in Eastern Nepal.

MATERIALS AND METHODS

A cross sectional study conducted over a period of one year (2011) at Microbiology laboratory, BP Koirala Institute of Health Sciences (BPKIHS). All clinical specimens received for culture and

Antimicrobial Susceptibility Testing (AST) from In-patient and Out-patient were included. Isolation of *P. aeruginosa* was done on Blood agar and MacConkey agar plates, further identification and antimicrobial susceptibility pattern against Piperacillin(100µg), Carbenicillin(100µg), Ceftazidime(30µg), Ceftriaxone(30µg), Tobramycin(10µg), Amikacin(10µg) and Ciprofloxacin(5µg) according was determined using Clinical and Laboratory Standards Institute (CLSI) guidelines on Muller Hinton Agar (MHA) by disc diffusion method.⁷ Standard antibiotics discs used in this study were purchased from HiMedia India. MBL production was determined using standard Ethylenediamine-tetraacetic acid (EDTA) disc synergy test method.⁸

RESULTS

One hundred thirty seven strains were confirmed as *P. aeruginosa* by specific biochemical test. Out of which 64.2% was isolated from exudates. Overall MBL production in *Pseudomonas* was found to be 31.4%, amongst which MBL production detected in clinical sample was 69.8%, 20.9% and 9.3% from exudates, blood and urine samples respectively. High degree of resistance was exhibited by *P. aeruginosa* against commonly used antimicrobial agents with highest being seen against Ceftazidime(89.83%) followed by Amikacin(86.1%), Piperacillin(81%) , almost all antibiotics showed equal number of resistance to MBL producing *P. aeruginosa* (Table-1).

Table 1: Antibiotic resistance pattern of MBL producing and non MBL producing *Pseudomonas aeruginosa*.

Antimicrobial Agents	MBL Producer (%)	MBL Non-Producer (%)	<i>Pseudomonas aeruginosa</i> Isolates (%)
Piperacillin (n=111)	35.13	64.87	81.00
Carbenicillin (n=109)	35.78	64.22	79.60
Ceftazidime (n=123)	33.33	66.67	89.60
Ceftriaxone (n=111)	35.13	64.87	63.50
Amikacin (n=118)	33.05	66.95	86.00
Tobramycin (n=95)	32.63	67.37	69.30
Ciprofloxacin (n=87)	34.48	65.52	81.00

DISCUSSION

Spread of MBLs capable of hydrolyzing carbapenems in *P. aeruginosa* and other major gram-negative pathogens has been a worrying problem in Japanese hospitals since early 1990, and recent reports suggest that a similar phenomenon is now also emerging in Europe and other parts of the world.⁹ The occurrence of an MBL-positive isolate in a hospital setting poses a therapeutic problem, as well as a serious concern for infection control management. The accurate identification and reporting of MBL-producing *P. aeruginosa* will aid infection control practitioners in preventing the spread of this multidrug-resistant isolates.¹⁰

Over a period of one year total, 137 isolates were processed for identification of MBL production. Among these majorities of isolates were from exudates followed by blood and urine. According to various studies, MBL production ranged from 7-65%.¹¹ In our context, overall MBL production was 31.4 %, where the percentage of MBL production among the carbapenem resistant isolates was found to be 35.78%. Our prevalence is correlating well with other studies (30.3 – 36%).^{10,12-14}

Our Prevalence of MBL in *P. aeruginosa* does not correlate with other studies across the country. In a study by Baniya B *et al*¹⁵, 16.4% of MBL production *P. aeruginosa* was reported and in another study performed in Kathmandu by Thapa P *et al.* reported 14.29% of *P. aeruginosa*.¹⁶ This variation seems to reflect the different diagnostic methods and the different rates of antibiotics used in different places.

Apart from being imipenem resistant, MBLs were resistant to important groups of antibiotics tested, including the third-generation cephalosporins, aminoglycosides, and quinolones a characteristic feature of MBL producers.^{10,13} For MBLs, limited treatment options are available and the only therapeutic option may be polymyxins, but it should not be used as monotherapy. It can be combined with an appropriate aminoglycoside.^{13,17}

This study revealed a high level of resistance to commonly used antimicrobials for treatment of infection with a notorious organism like *P. aeruginosa*, in addition to the alarming threat of MBL production necessitates a routine screening for MBL production. Also, a more effective, less toxic and cheap antimicrobial for the future is imperative.

REFERENCES

- Richards M. J, Edwards J. R, Culver D. H and. Gaynes R. P. "Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System" *Crit. Care Med*, 1999; 27: 887–92.
- Aloush V, Navon-venezia S, Seigman-igra Y, Cabili S, and Carmeli Y. "Multidrug-Resistant *Pseudomonas aeruginosa*: Risk Factors and Clinical Impact," *Antimicrob Agents Chemother*, 2006; 50: 43–8.
- World Health Organization, "The evolving threat of antimicrobial resistance: Options for action," *WHO Publ* 2014: 1–119.
- Gad G. F, El-Domany R. A, Zaki S, and Ashour H. M. "Characterization of *Pseudomonas aeruginosa* isolated from clinical and environmental samples in Minia, Egypt: Prevalence, antibiogram and resistance mechanisms," *J Antimicrob Chemother* 2007; 60: 1010–17.
- Vahdani M, Azimi L, Asghari B, Bazmi F, and. Rastegar L. A. "Phenotypic screening of extended-spectrum β -lactamase and metallo- β -lactamase in multidrug-resistant *Pseudomonas aeruginosa* from infected burns," *Ann Burns Fire Disasters*, 2012; 25: 78–81.
- Hammami S, Boutiba-Ben Boubaker I, Ghazzi R, Saidani M, Amine S, and Ben Redjeb S, "Nosocomial outbreak of imipenem-resistant *Pseudomonas aeruginosa* producing VIM-2 metallo- β -lactamase in a kidney transplantation unit," *Diagn Pathol* 2011; 6: 106.
- Cockerill FR, Wikler MA, Bush K *et al.* Performance standards for antimicrobial susceptibility testing twenty-first informational supplement. *Clinical and Laboratory Standards Institute* 2011; 31: 1-172.
- Lee K, Chong Y, Shin H. B, Kim Y. A, Yong D, and Yum J. H, "Modified Hodge and EDTA-disk synergy tests to screen metallo- β -lactamase-producing strains of *Pseudomonas* and *Acinetobacter* species." *Clin. Microbiol. Infect* 2001; 7: 88–91.
- Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, and Fontana R, "Hospital Outbreak of Carbapenem-Resistant *Pseudomonas aeruginosa* Producing VIM-1, a Novel Transferable Metallo- β -Lactamase," *Clin Infect Dis* 2000; 31: 1119–25.
- Pitout JDD, Gregson DB, Poirel L, McClure J and Le P. Detection of *Pseudomonas aeruginosa* Producing Metallo- β -Lactamases in a Large Centralized Laboratory," *J Clin Microbiol* 2005; 43: 3129–35.
- Al-charrakh AH, Al-awadi SJ, Mohammed A. S, "Detection of Metallo- β -Lactamase Producing *Pseudomonas aeruginosa* Isolated from Public and Private Hospitals in Baghdad , Iraq," *Acta Med Iran* 2014; 54: 107-13.
- Marra AR, Pereira CA, Gales AC *et al.*, "Bloodstream infections with metallo-beta-lactamase-producing *Pseudomonas aeruginosa*: epidemiology, microbiology, and clinical outcomes." *Antimicrob. Agents Chemother*, 2006; 50: 388–90.
- De A, Kumar S, and Baveja S, "Prevalence of

- metallo- β -lactamase producing *Pseudomonas aeruginosa* and *Acinetobacter* species in intensive care areas in a tertiary care hospital,” *Indian J Crit Care Med* 2010; 14: 217.
14. Franco M. R. G, Caiaffa-Filho H. H, Burattini M. N, and Rossi F. “Metallo-beta-lactamases among imipenem-resistant *Pseudomonas aeruginosa* in a Brazilian university hospital,” *Clinics* 2010; 65: 825–9.
 15. Baniya B, Pant N.D, Neupane S, Belbase S, Khatiwada S, Yadav U. *et al.*, “Biofilm and metallo beta-lactamase production among the strains of *Pseudomonas aeruginosa* and *Acinetobacter* spp. at a tertiary care hospital in Kathmandu, Nepal,” *Ann Clin Microbiol Antimicrob* 2017; 16: 6–9.
 16. Thapa P, Bhandari D, Shrestha D *et al.* “A hospital based surveillance of metallo-beta-lactamase producing gram negative bacteria in Nepal by imipenem-EDTA disk method,” *BMC Res. Notes*, 2017; 10: 1–6.
 17. Walsh TR, Toleman MA, Poirel L and Nordman P. “Metallo- β -Lactamases : the Quiet before the Storm,” *Clin Microbiol Rev* 2005; 18: 306–25.